Does HIV-1 co-receptor tropism correlate with fibrosis progression in HIV/HCV co-infected patients?

A. Saracino, G. Bruno, L. Scudeller, G. Punzi, A. Lagioia, N. Ladisa, L. Monno, G. Angarano

Research output: Contribution to journalArticle

Abstract

Background: In HIV/HCV co-infected patients, HIV-1 gp120 activates human hepatic stellate cells (HSCs) which play a key role in fibrosis pathogenesis. It is still unclear whether pro-fibrogenic effects are more attributable to X4 or R5 strains in vivo. Objective: To assess if HIV-1 X4 or R5 variants are associated with a different progression of fibrosis. Study design: A total of 105 HIV/HCV co-infected patients were submitted to gp120 sequencing on proviral DNA and classified as X4 or R5 based on g2p (20% false positive rate). The fibrosis evolution was retrospectively determined by means of APRI and FIB-4 scores at 3-month intervals from the first anti-HCV-positive test. The association of co-receptor tropism with increased fibrosis scores was evaluated by linear mixed models. Results: X4 variants were found in 41 patients (39%). The median observation period was similar in X4 and R5 patients (17 years). No difference was observed between the two groups of patients, except for nadir CD4 which was lower in X4 compared to R5 (percentage, p=. 0.005, and absolute number, p=. 0.005). X4 and R5 patients did not significantly differ for FIB-4 and APRI score over time (p=0.5, and p=. 0.1, respectively). No association between HCV-RNA levels over time and co-receptor tropism was noted (p=0.9). Conversely, a significant correlation of fibrosis scores with gamma-glutamyl transferase levels, lower current CD4 count, HIV viremia and use of antiretrovirals was observed. Conclusions: This retrospective analysis of fibrosis evolution did not support the evidence of a differing pro-fibrogenic activity for X4 and R5 HIV-1 variants in HIV/HCV co-infected patients.

Original languageEnglish
Pages (from-to)167-171
Number of pages5
JournalJournal of Clinical Virology
Volume59
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Tropism
HIV-1
Fibrosis
HIV
Hepatic Stellate Cells
Viremia
CD4 Lymphocyte Count
Transferases
Linear Models
Observation
RNA
DNA

Keywords

  • APRI
  • Co-receptor tropism
  • FIB-4
  • HIV/HCV co-infection
  • Liver fibrosis

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Does HIV-1 co-receptor tropism correlate with fibrosis progression in HIV/HCV co-infected patients? / Saracino, A.; Bruno, G.; Scudeller, L.; Punzi, G.; Lagioia, A.; Ladisa, N.; Monno, L.; Angarano, G.

In: Journal of Clinical Virology, Vol. 59, No. 3, 03.2014, p. 167-171.

Research output: Contribution to journalArticle

Saracino, A. ; Bruno, G. ; Scudeller, L. ; Punzi, G. ; Lagioia, A. ; Ladisa, N. ; Monno, L. ; Angarano, G. / Does HIV-1 co-receptor tropism correlate with fibrosis progression in HIV/HCV co-infected patients?. In: Journal of Clinical Virology. 2014 ; Vol. 59, No. 3. pp. 167-171.
@article{91e3a459024649e88e65546882fa2703,
title = "Does HIV-1 co-receptor tropism correlate with fibrosis progression in HIV/HCV co-infected patients?",
abstract = "Background: In HIV/HCV co-infected patients, HIV-1 gp120 activates human hepatic stellate cells (HSCs) which play a key role in fibrosis pathogenesis. It is still unclear whether pro-fibrogenic effects are more attributable to X4 or R5 strains in vivo. Objective: To assess if HIV-1 X4 or R5 variants are associated with a different progression of fibrosis. Study design: A total of 105 HIV/HCV co-infected patients were submitted to gp120 sequencing on proviral DNA and classified as X4 or R5 based on g2p (20{\%} false positive rate). The fibrosis evolution was retrospectively determined by means of APRI and FIB-4 scores at 3-month intervals from the first anti-HCV-positive test. The association of co-receptor tropism with increased fibrosis scores was evaluated by linear mixed models. Results: X4 variants were found in 41 patients (39{\%}). The median observation period was similar in X4 and R5 patients (17 years). No difference was observed between the two groups of patients, except for nadir CD4 which was lower in X4 compared to R5 (percentage, p=. 0.005, and absolute number, p=. 0.005). X4 and R5 patients did not significantly differ for FIB-4 and APRI score over time (p=0.5, and p=. 0.1, respectively). No association between HCV-RNA levels over time and co-receptor tropism was noted (p=0.9). Conversely, a significant correlation of fibrosis scores with gamma-glutamyl transferase levels, lower current CD4 count, HIV viremia and use of antiretrovirals was observed. Conclusions: This retrospective analysis of fibrosis evolution did not support the evidence of a differing pro-fibrogenic activity for X4 and R5 HIV-1 variants in HIV/HCV co-infected patients.",
keywords = "APRI, Co-receptor tropism, FIB-4, HIV/HCV co-infection, Liver fibrosis",
author = "A. Saracino and G. Bruno and L. Scudeller and G. Punzi and A. Lagioia and N. Ladisa and L. Monno and G. Angarano",
year = "2014",
month = "3",
doi = "10.1016/j.jcv.2013.12.009",
language = "English",
volume = "59",
pages = "167--171",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Does HIV-1 co-receptor tropism correlate with fibrosis progression in HIV/HCV co-infected patients?

AU - Saracino, A.

AU - Bruno, G.

AU - Scudeller, L.

AU - Punzi, G.

AU - Lagioia, A.

AU - Ladisa, N.

AU - Monno, L.

AU - Angarano, G.

PY - 2014/3

Y1 - 2014/3

N2 - Background: In HIV/HCV co-infected patients, HIV-1 gp120 activates human hepatic stellate cells (HSCs) which play a key role in fibrosis pathogenesis. It is still unclear whether pro-fibrogenic effects are more attributable to X4 or R5 strains in vivo. Objective: To assess if HIV-1 X4 or R5 variants are associated with a different progression of fibrosis. Study design: A total of 105 HIV/HCV co-infected patients were submitted to gp120 sequencing on proviral DNA and classified as X4 or R5 based on g2p (20% false positive rate). The fibrosis evolution was retrospectively determined by means of APRI and FIB-4 scores at 3-month intervals from the first anti-HCV-positive test. The association of co-receptor tropism with increased fibrosis scores was evaluated by linear mixed models. Results: X4 variants were found in 41 patients (39%). The median observation period was similar in X4 and R5 patients (17 years). No difference was observed between the two groups of patients, except for nadir CD4 which was lower in X4 compared to R5 (percentage, p=. 0.005, and absolute number, p=. 0.005). X4 and R5 patients did not significantly differ for FIB-4 and APRI score over time (p=0.5, and p=. 0.1, respectively). No association between HCV-RNA levels over time and co-receptor tropism was noted (p=0.9). Conversely, a significant correlation of fibrosis scores with gamma-glutamyl transferase levels, lower current CD4 count, HIV viremia and use of antiretrovirals was observed. Conclusions: This retrospective analysis of fibrosis evolution did not support the evidence of a differing pro-fibrogenic activity for X4 and R5 HIV-1 variants in HIV/HCV co-infected patients.

AB - Background: In HIV/HCV co-infected patients, HIV-1 gp120 activates human hepatic stellate cells (HSCs) which play a key role in fibrosis pathogenesis. It is still unclear whether pro-fibrogenic effects are more attributable to X4 or R5 strains in vivo. Objective: To assess if HIV-1 X4 or R5 variants are associated with a different progression of fibrosis. Study design: A total of 105 HIV/HCV co-infected patients were submitted to gp120 sequencing on proviral DNA and classified as X4 or R5 based on g2p (20% false positive rate). The fibrosis evolution was retrospectively determined by means of APRI and FIB-4 scores at 3-month intervals from the first anti-HCV-positive test. The association of co-receptor tropism with increased fibrosis scores was evaluated by linear mixed models. Results: X4 variants were found in 41 patients (39%). The median observation period was similar in X4 and R5 patients (17 years). No difference was observed between the two groups of patients, except for nadir CD4 which was lower in X4 compared to R5 (percentage, p=. 0.005, and absolute number, p=. 0.005). X4 and R5 patients did not significantly differ for FIB-4 and APRI score over time (p=0.5, and p=. 0.1, respectively). No association between HCV-RNA levels over time and co-receptor tropism was noted (p=0.9). Conversely, a significant correlation of fibrosis scores with gamma-glutamyl transferase levels, lower current CD4 count, HIV viremia and use of antiretrovirals was observed. Conclusions: This retrospective analysis of fibrosis evolution did not support the evidence of a differing pro-fibrogenic activity for X4 and R5 HIV-1 variants in HIV/HCV co-infected patients.

KW - APRI

KW - Co-receptor tropism

KW - FIB-4

KW - HIV/HCV co-infection

KW - Liver fibrosis

UR - http://www.scopus.com/inward/record.url?scp=84893911077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893911077&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2013.12.009

DO - 10.1016/j.jcv.2013.12.009

M3 - Article

C2 - 24461764

AN - SCOPUS:84893911077

VL - 59

SP - 167

EP - 171

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 3

ER -